Circulating vitamin D level and mortality in prostate cancer patients: a dose-response meta-analysis
Endocrine Connections DOI: https://doi.org/10.1530/EC-18-0283
Zhenyu Song 1 , Qiuming Yao 2 , Zhiyuan Zhuo 3 , Zhe Ma 4 and Gang Chen 5 chgan305 at 163.com
prostate cancer mortality
- Prostate Cancer long term survival 1.7 X more likely if high level of vitamin D – Jan 2016
- High PSA readings with Prostate Cancer 4 times more likely if poor Vitamin D receptor – March 2016
- Prostate Cancer and Vitamin D studies Overview
- Aggressive Prostate Cancer in blacks with low vitamin D – 7X more likely if added Calcium – Jan 2017
- Probably better than 40% reduction if 40 ng of Vitamin D and minimize Calcium
- Prostate cancer in black men is 1.6 times more likely if a poor Vitamin D Receptor – Feb 2017 Probably better than 40% reduction if 40 ng of Vitamin D and improve Receptor activation (8 ways)
- Low-Grade Prostate Cancer 70 percent less likely to progress if good level of Omega-3 – June 2018
- Might prevent Prostate Cancer with Omega-3 and Vitamin D
Studies in all 3 categories: Prostate Cancer, Meta-analysis and Mortality
Download the PDF from Vitamin D Life
Background: Previous studies investigating the association of circulating 25-hydroxyvitamin D level with prognosis of prostate cancer yielded controversial results. We conducted a dose-response meta-analysis to elucidate the relationship.
Methods: PubMed and Embase were searched for eligible studies up to July 15, 2018. We performed a dose-response meta-analysis using random-effect model to calculate the summary hazard ratio (HR) and 95% confidence interval (CI) of mortality in patients with prostate cancer.
Results: Seven eligible cohort studies with 7,808 participants were included. The results indicated that higher vitamin D level could reduce the risk of death among prostate cancer patients. The summary HR of prostate cancer-specific mortality correlated with an increment of every 20 nmol/L in circulating vitamin D level was 0.91, with 95% CI 0.87-0.97, P=0.002. The HR for all-cause mortality with the increase of 20 nmol/L vitamin D was 0.91 (95% CI: 0.84-0.98, P=0.01). Sensitivity analysis suggested the pooled HRs were stable and not obviously changed by any single study. No evidence of publications bias was observed.
Conclusion: This meta-analysis suggested that higher 25-hydroxyvitamin D level was associated with a reduction of mortality in prostate cancer patients and vitamin D is an important protective factor in the progression and prognosis of prostate cancer.